Who
Mark William Lowdell
Chief Scientific Officer
Company insider
Files Form 4 as: Chief Scientific Officer, INmune Bio.
In numbers
- Trades disclosed
- 30
- Buys
- 2
- Sells
- 5
- Bought
- $138K
- Sold
- $674K
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 11 Sep 2019
- Last trade
- 2 Jul 2026
- Last filed
- 7 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 2 Jul 2026filed 7 Jul 2026 | INMB INmune BioBiotechnology | SEC FORM 4 Code M | $10K7,211 at $1.40 | filing |
| 2 Jul 2026filed 7 Jul 2026 | INMB INmune Biooption or derivative · Biotechnology | SEC FORM 4 Code X | $9017,211 at $0.125 | filing |
| 2 Jul 2026filed 7 Jul 2026 | INMB INmune Biooption or derivative · Biotechnology | SEC FORM 4 Code X | $9377,211 at $0.13 | filing |
| 2 Jul 2026filed 7 Jul 2026 | INMB INmune BioBiotechnology | SEC FORM 4 Code M | $10K7,211 at $1.40 | filing |
| 1 Dec 2025filed 2 Dec 2025 | INMB INmune Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —600,000 at $0.00 | filing |
| 18 Nov 2025filed 18 Nov 2025 | INMB INmune Biooption or derivative · Biotechnology | SEC FORM 4 Code D | —400,000 | filing |
| 18 Nov 2025filed 18 Nov 2025 | INMB INmune Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —400,000 | filing |
| 18 Nov 2025filed 18 Nov 2025 | INMB INmune Biooption or derivative · Biotechnology | SEC FORM 4 Code D | —180,000 | filing |
| 18 Nov 2025filed 18 Nov 2025 | INMB INmune Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —180,000 | filing |
| 18 Nov 2025filed 18 Nov 2025 | INMB INmune Biooption or derivative · Biotechnology | SEC FORM 4 Code D | —104,000 | filing |
| 18 Nov 2025filed 18 Nov 2025 | INMB INmune Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —104,000 | filing |
| 18 Nov 2025filed 18 Nov 2025 | INMB INmune Biooption or derivative · Biotechnology | SEC FORM 4 Code D | —140,000 | filing |
| 18 Nov 2025filed 18 Nov 2025 | INMB INmune Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —140,000 | filing |
| 18 Nov 2025filed 18 Nov 2025 | INMB INmune Biooption or derivative · Biotechnology | SEC FORM 4 Code D | —100,000 | filing |
| 18 Nov 2025filed 18 Nov 2025 | INMB INmune Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —100,000 | filing |
| 5 Dec 2024filed 9 Dec 2024 | INMB INmune Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —140,000 at $0.00 | filing |
| 14 May 2024filed 16 May 2024 | INMB INmune Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
| 19 Apr 2024filed 24 Apr 2024 | INMB INmune Biooption or derivative · Biotechnology | SEC FORM 4 Code P | $1,87514,423 at $0.13 | filing |
| 19 Apr 2024filed 24 Apr 2024 | INMB INmune BioBiotechnology | SEC FORM 4 Bought | $120K14,423 at $8.32 | filing |
| 19 Apr 2024filed 23 Apr 2024 | INMB INmune Biooption or derivative · Biotechnology | SEC FORM 4 Code A | $1,87514,423 at $0.13 | filing |
News
Financial Survey: INmune Bio (NASDAQ:INMB) vs. Alkermes (NASDAQ:ALKS)INMB · themarketsdaily.com · 20 Oct 2026INmune Bio Teams with Quantum Computing Inc. to Target New Indications for XProINMB · ibtimes.com · 15 Oct 2026INmune Bio : Quotes, Address, ContactINMB · news-medical.net · 15 Oct 2026
0 headlines in the last 90 days name Mark William Lowdell; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.